Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
Express News | Atara Biotherapeutics Inc : Mizuho Raises to Outperform From Neutral; Cuts Target Price to $18 From $25
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Just Reported Earnings, And Analysts Cut Their Target Price
Atara Biotherapeutics Second Quarter 2024 Earnings: Misses Expectations
Atara Biotherapeutics Is Maintained at Buy by Canaccord Genuity
Atara Biotherapeutics Analyst Ratings
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics: A Promising Buy on Pipeline Progress and Strong Financial Outlook
Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation
Atara Biotherapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q2 Revenue $28.6M
Express News | Atara Biotherapeutics Inc - Tab-Cel(®) U.S. Bla Accepted Under Priority Review With Pdufa Action Date of January 15, 2025
Express News | Atara Biotherapeutics Inc - Cokey Nguyen, Ph.d., Currently Chief Scientific and Technical Officer, to Be Appointed President and CEO
Express News | Atara Biotherapeutics Inc - Effective September 9, 2024, Pascal Touchon to Assume Role of Chairman of Board of Directors of Atara
Express News | Atara Biotherapeutics Inc - Cash Runway Into 2027 Enables Key Pipeline Readouts
Express News | Atara Biotherapeutics Q2 EPS USD -3.1
Express News | Atara Biotherapeutics Q2 Revenue USD 28.64 Million Vs. IBES Estimate USD 40 Million
Express News | Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Express News | Atara Biotherapeutics Q2 Operating Income USD -18.231 Million
Express News | Atara Biotherapeutics Q2 Net Income USD -19.049 Million
No Data